Francesco Raspagliesi

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1894088/francesco-raspagliesi-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

324 9,155 47 84 g-index

346 11,193 3.9 5.89 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
324	Clear cell carcinoma of the endometrium <i>Gynecologic Oncology</i> , 2022 ,	4.9	4
323	SUCCOR cone study: conization before radical hysterectomy <i>International Journal of Gynecological Cancer</i> , 2022 ,	3.5	5
322	Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic Journal of Gynecologic Oncology, 2022 , 33, e10	4	1
321	BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer <i>Tumori</i> , 2022 , 3008916211073621	1.7	1
320	Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patientsPprognostic assessment <i>European Journal of Cancer</i> , 2021 , 161, 55-63	7.5	1
319	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. <i>New England Journal of Medicine</i> , 2021 , 385, 2123-2131	59.2	23
318	Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. <i>Targeted Oncology</i> , 2021 , 16, 59-68	5	4
317	The Adoption of Radiomics and machine learning improves the diagnostic processes of women with Ovarian MAsses (the AROMA pilot study). <i>Journal of Ultrasound</i> , 2021 , 24, 429-437	3.4	8
316	Conization and lymph node evaluation as a fertility-sparing treatment for early stage cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 457-461	3.5	5
315	Minimally invasive surgery in cervical cancer. <i>Minerva Obstetrics and Gynecology</i> , 2021 , 73,		1
314	Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study. <i>Gynecologic Oncology</i> , 2021 , 161, 122-129	4.9	9
313	Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer. Cancers, 2021, 13,	6.6	5
312	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1031-1036	3.5	1
311	A decision support system based on radiomics and machine learning to predict the risk of malignancy of ovarian masses from transvaginal ultrasonography and serum CA-125. <i>European Radiology Experimental</i> , 2021 , 5, 28	4.5	1
310	Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1212-1219	3.5	2
309	Investigating the Role of Minimally Invasive Surgery in Patients with Chronic Pulmonary Disease. Journal of Investigative Surgery, 2021 , 34, 80-81	1.2	
308	Preoperative Conization and Risk of Recurrence in Patients Undergoing Laparoscopic Radical Hysterectomy for Early Stage Cervical Cancer: A Multicenter Study. <i>Journal of Minimally Invasive Gynecology</i> , 2021 , 28, 117-123	2.2	32

(2020-2021)

307	Spotlight on the role of human papillomavirus vaccines. <i>Gynecologic Oncology</i> , 2021 , 160, 346-350	4.9	6
306	Technique for Improving the Adoption of Minimally Invasive Surgery in Challenging Cases. <i>Journal of Investigative Surgery</i> , 2021 , 34, 334	1.2	
305	Sentinel Node Mapping in Endometrial Cancer. <i>Journal of Investigative Surgery</i> , 2021 , 34, 677-678	1.2	
304	Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 5	12.8	2
303	Sentinel Node Mapping at the Time of COVID-19 Outbreak. <i>Journal of Investigative Surgery</i> , 2021 , 1-2	1.2	0
302	Uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021 , 162, 226-234	4.9	12
301	Transmission of SARS-CoV-2 in Surgical Smoke during Laparoscopy: A Prospective, Proof-of-concept Study. <i>Journal of Minimally Invasive Gynecology</i> , 2021 , 28, 1519-1525	2.2	5
300	Factors predicting morbidity in surgically-staged high-risk endometrial cancer patients. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021 , 266, 169-174	2.4	1
299	Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study. <i>Gynecologic Oncology</i> , 2021 , 162, 590-598	4.9	5
298	Fertility preservation in childhood and adolescent female tumor survivors. <i>Fertility and Sterility</i> , 2021 , 116, 1087-1095	4.8	4
297	The impact of HPV-specific infection in women diagnosed with atypical glandular cells: Results from the HPV-AGC study. <i>Pathology Research and Practice</i> , 2020 , 216, 153184	3.4	1
296	Ten-year follow-up study of long-term outcomes after conservative surgery for early-stage ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2020 , 150, 169-176	4	5
295	Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone: Long-term results of a propensity-matched analysis. <i>Gynecologic Oncology</i> , 2020 , 158, 77-83	4.9	19
294	Management of patients with ovarian cancer in the COVID-19 era. <i>Journal of Surgical Oncology</i> , 2020 , 122, 122-123	2.8	11
293	Immunotherapy for platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 158, 484-488	4.9	20
292	Cancer patients affected by COVID-19: Experience from Milan, Lombardy. <i>Gynecologic Oncology</i> , 2020 , 158, 262-265	4.9	27
291	Surgical oncology at the time of COVID-19 outbreak. <i>Journal of Surgical Oncology</i> , 2020 , 122, 115-116	2.8	5
290	Primary conization overcomes the risk of developing local recurrence following laparoscopic radical hysterectomy in early stage cervical cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2020 , 151, 43-48	4	5

289	Oocyte cryopreservation in two women with borderline ovarian tumor recurrence. <i>Journal of Assisted Reproduction and Genetics</i> , 2020 , 37, 1213-1216	3.4	4
288	Sentinel lymph node mapping in endometrial cancer: performance of hysteroscopic injection of tracers. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 332-338	3.5	7
287	Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2020 , 157, 293-298	4.9	12
286	European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 3-14	3.5	16
285	Patterns of recurrence after laparoscopic versus open abdominal radical hysterectomy in patients with cervical cancer: a propensity-matched analysis. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 987-992	3.5	13
284	Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women. <i>Journal of Gynecologic Oncology</i> , 2020 , 31, e60	4	6
283	Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma. <i>Journal of Gynecologic Oncology</i> , 2020 , 31, e64	4	17
282	Gynecologic oncology at the time of COVID-19 outbreak. <i>Journal of Gynecologic Oncology</i> , 2020 , 31, e72	4	16
281	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. <i>Journal of Gynecologic Oncology</i> , 2020 , 31, e92	4	10
280	Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. <i>Gynecologic Oncology</i> , 2020 , 156, 38-44	4.9	27
279	Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. <i>Gynecologic Oncology</i> , 2020 , 156, 523-529	4.9	17
278	Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 56-61	3.5	5
277	Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity; ABRAX (ABandoning RAd hyst in cerviX cancer). <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 261-264	3.5	9
276	Presence of Glandular Cells at the Preoperative Cervical Cytology and Local Recurrence in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 522-528	3.2	22
275	Malignant peritoneal cytology in endometrial cancer. European Journal of Cancer, 2020, 140, 147-148	7.5	2
274	Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group. <i>European Journal of Cancer</i> , 2020 , 140, 1-10	7.5	7
273	From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?. <i>Vaccines</i> , 2020 , 8,	5.3	6
272	Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison. <i>Vaccines</i> , 2020 , 8,	5.3	12

(2019-2020)

271	Trends in prevalence in human papillomavirus types and their association with cervical dysplasia: an analysis on 15 138 women over 20 years. <i>European Journal of Cancer Prevention</i> , 2020 , 29, 452-457	2	1
270	Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial. <i>European Journal of Cancer</i> , 2020 , 137, 69-80	7.5	14
269	Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study. <i>Gynecologic Oncology</i> , 2020 , 159, 636-641	4.9	20
268	Detection of Ovarian Cancer through Exhaled Breath by Electronic Nose: A Prospective Study. <i>Cancers</i> , 2020 , 12,	6.6	7
267	Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers. <i>Clinical Sarcoma Research</i> , 2020 , 10, 17	2.5	3
266	Investigating the Role of Minimally Invasive Radical Hysterectomy in Cervical Cancer. <i>Journal of Investigative Surgery</i> , 2020 , 33, 387-388	1.2	3
265	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , 2020 , 60, 344-350	12.7	10
264	Minimally Invasive Surgery at the Time of COVID-19: The OR Staff Needs Protection. <i>Journal of Minimally Invasive Gynecology</i> , 2020 , 27, 1221	2.2	17
263	The role of sentinel lymph node mapping in lower genital tract melanoma. <i>Minerva Ginecologica</i> , 2020 , 72, 384-390	1.2	2
262	Advances in laparoscopic surgery for cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 143, 76-80	7	10
261	Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2019 , 145, 28-33	4	4
260	Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study. <i>Gynecologic Oncology</i> , 2019 , 154, 323-327	4.9	18
259	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 862-876	21.7	48
258	Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 711-720	3.5	6
257	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019 , 154, 83-88	4.9	4
256	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. <i>Annals of Oncology</i> , 2019 , 30, 1080-1087	10.3	237
255	RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019 , 237, 93-99	2.4	9
254	Long-term results of fertility-sparing treatment for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2019 , 154, 89-94	4.9	19

253	Does the adoption of sentinel node mapping allow to design a new trial testing the value of retroperitoneal staging in endometrial cancer?. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e68	4	1
252	Nomogram-based prediction of cervical dysplasia persistence/recurrence. <i>European Journal of Cancer Prevention</i> , 2019 , 28, 435-440	2	9
251	A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling. <i>Cancers</i> , 2019 , 11,	6.6	6
250	Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e27	4	15
249	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019 , 153, 535-540	4.9	14
248	Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis. <i>Tumori</i> , 2019 , 105, 282-287	1.7	7
247	Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2019 , 153, 676-683	4.9	60
246	Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study. <i>Tumori</i> , 2019 , 105, 253-258	1.7	3
245	The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e4	4	12
244	Treatment modalities for recurrent high-grade vaginal intraepithelial neoplasia. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e20	4	9
243	Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer. <i>Tumori</i> , 2019 , 105, 92-97	1.7	15
242	High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. <i>Oncolmmunology</i> , 2019 , 8, e1614856	7.2	16
241	Radical surgery for cervical cancer. <i>Lancet Oncology, The</i> , 2019 , 20, 1198-1199	21.7	1
240	Cervical intraepithelial neoplasia in women who had vaccination against HPV. <i>International Journal of Gynecology and Obstetrics</i> , 2019 , 147, 233-237	4	4
239	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 22730-22736	11.5	26
238	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. <i>Frontiers in Immunology</i> , 2019 , 10, 2514	8.4	5
237	Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer) <i>Journal of Clinical Oncology</i> , 2019 , 37, 5516-5516	2.2	4
236	Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e94	4	18

(2018-2019)

235	EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in	2.2	
234	relapsed platinum-sensitive ovarian cancer patients <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS5605-T A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. <i>New England Journal of Medicine</i> , 2019 , 380, 822-832	59.2	206
233	Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells. <i>Gynecologic Oncology</i> , 2019 , 153, 670-675	4.9	34
232	Impact of gene-specific germline pathogenic variants on presentation of endometrial cancer in Lynch syndrome. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 705-710	3.5	7
231	Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage IIICp cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 1355-1360	3.5	8
230	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019 , 24, e536-e541	5.7	12
229	Re: Concordance Between Intracervical and Fundal Injections for Sentinel Node Mapping in Patients With Endometrial Cancer? A Study Using Intracervical Radiotracer and Fundal Blue Dye Injections. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 848-849	1.7	1
228	Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e57	4	32
227	New prophylactics human papilloma virus (HPV) vaccines against cervical cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2019 , 39, 1-10	1.3	32
226	Regarding "When Less Is More: Minimally Invasive Surgery Compared to Laparotomy for Interval Debulking after Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer". <i>Journal of Minimally Invasive Gynecology</i> , 2019 , 26, 573-574	2.2	1
225	Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved. <i>Journal of Assisted Reproduction and Genetics</i> , 2019 , 36, 569-578	3.4	6
224	Minimally Invasive Nerve-Sparing Radical Hysterectomy: A Win-Win Scenario. <i>Journal of Investigative Surgery</i> , 2019 , 32, 281-282	1.2	3
223	Predicting Factors for High-Grade Cervical Dysplasia in Women With Low-Grade Cervical Cytology and Nonvisible Squamocolumnar Junction. <i>Reproductive Sciences</i> , 2019 , 26, 44-48	3	2
222	Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach. <i>European Journal of Cancer Prevention</i> , 2019 , 28, 81-86	2	11
221	Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2018 , 29, 1189-1194	10.3	4
220	Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndrome. <i>JAMA Oncology</i> , 2018 , 4, 889	13.4	
219	Role of bevacizumab in uterine leiomyosarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 126, 45-51	7	3
218	Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 766-770	3.6	18

217	The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 122, 92-97	7	37
216	Nerve-Sparing Approach Improves Outcomes of Patients Undergoing Minimally Invasive Radical Hysterectomy: A Systematic Review and Meta-Analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2018 , 25, 402-410	2.2	16
215	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. <i>Radiotherapy and Oncology</i> , 2018 , 127, 404-416	5.3	131
214	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 641-655	3.5	164
213	Invasive Paget Disease of the Vulva. International Journal of Gynecological Cancer, 2018, 28, 176-182	3.5	15
212	Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features. <i>Oncology</i> , 2018 , 94, 1-6	3.6	5
211	A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e40	4	11
210	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018 , 119, 565-571	8.7	8
209	Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e66	4	16
208	Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 146	12.8	17
207	LASER treatment for women with high-grade vaginal intraepithelial neoplasia: A propensity-matched analysis on the efficacy of ablative versus excisional procedures. <i>Lasers in Surgery and Medicine</i> , 2018 , 50, 933-939	3.6	14
206	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018,	5.1	63
205	Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 1501-1509	4.4	24
204	Early diagnosis in endometrial cancer minimizes the impact of treatments. <i>American Journal of Obstetrics and Gynecology</i> , 2018 , 219, 631-632	6.4	1
203	Lynch syndrome - Muir-Torre variant: implication in gynecologic oncology. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e84	4	1
202	Oncologic effectiveness of nerve-sparing radical hysterectomy in cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e41	4	4
201	The impact of morcellation on survival outcomes of undiagnosed uterine sarcoma. <i>Gynecologic Oncology Reports</i> , 2018 , 23, 37-38	1.3	1
200	Ovarian preservation in locally advanced cervical cancer undergoing neoadjuvant chemotherapy and radical surgery. <i>Minerva Obstetrics and Gynecology</i> , 2018 , 70, 357-363		

Wertheim-Meigs Abdominal Radical Hysterectomy and Lymphadenectomy **2018**, 1209-1212

198	Rectus Abdominis Myofascial Flap for Vaginal Reconstruction After Pelvic Exenteration. <i>Annals of Plastic Surgery</i> , 2018 , 81, 576-583	1.7	10
197	Tailoring adjuvant treatment in patients with uterine cancer. Lancet Oncology, The, 2018, 19, e655	21.7	1
196	Current landscape and future perspective of sentinel node mapping in endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e94	4	11
195	Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC-IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 1706-1713	3.5	3
194	The addition of lymphadenectomy to secondary cytoreductive surgery in comparison with bulky node resection in patients with recurrent ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2018 , 143, 319-324	4	5
193	Factors Predictive of 90-Day Morbidity, Readmission, and Costs in Patients Undergoing Pelvic Exenteration. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 975-982	3.5	5
192	Potential impact of introducing a nonavalent HPV vaccination. <i>International Journal of Gynecology and Obstetrics</i> , 2018 , 142, 338-342	4	7
191	Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017 , 210, 157-165	2.4	20
190	Minimally Invasive Surgical Staging in Early-stage Ovarian Carcinoma: A Systematic Review and Meta-analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2017 , 24, 552-562	2.2	24
189	The association of pre-treatment HPV subtypes with recurrence of VIN. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017 , 211, 37-41	2.4	11
188	Investigational drugs for the treatment of cervical cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 389-402	5.9	31
187	Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1275-1279	4.9	8
186	The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer. Expert Opinion on Drug Safety, 2017, 16, 687-696	4.1	6
185	Sentinel-lymph-node mapping in endometrial cancer. <i>Lancet Oncology, The</i> , 2017 , 18, e234	21.7	8
184	Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. <i>Journal of Minimally Invasive Gynecology</i> , 2017 , 24, 837-842	2.2	14
183	Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project. <i>Supportive Care in Cancer</i> , 2017 , 25, 1743-1748	3.9	
182	Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 514-522	3.5	13

181	Treatment of Genital Melanoma: Are We Ready for Innovative Therapies?. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1063	3.5	2
180	Impact of Surgical Route in Influencing the Risk of Lymphatic Complications After Ovarian Cancer Staging. <i>Journal of Minimally Invasive Gynecology</i> , 2017 , 24, 739-746	2.2	11
179	Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytology. <i>International Journal of Gynecology and Obstetrics</i> , 2017 , 138, 63	2-68	14
178	Impact of Morcellation of Occult Malignancies at the Time of Vaginal Hysterectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2017 , 24, 876-877	2.2	
177	Type-specific HPV infection correlates with risk of recurrence of vulvar intraepithelial neoplasia usual type. <i>International Journal of Cancer</i> , 2017 , 140, 1702	7.5	2
176	Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. <i>Gynecologic Oncology</i> , 2017 , 144, 256-259	4.9	26
175	The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1856-1862	3.5	23
174	3D vision improves outcomes in early cervical cancer treated with laparoscopic type B radical hysterectomy and pelvic lymphadenectomy. <i>Tumori</i> , 2017 , 103, 76-80	1.7	6
173	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3347-3353	2.2	45
172	Introducing nerve-sparing approach during minimally invasive radical hysterectomy for locally-advanced cervical cancer: A multi-institutional experience. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 2150-2156	3.6	17
171	Sentinel node mapping in endometrial cancer following Hysteroscopic injection of tracers: A single center evaluation over 200 cases. <i>Gynecologic Oncology</i> , 2017 , 146, 525-530	4.9	25
170	Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses. <i>Gynecologic Oncology</i> , 2017 , 147, 61-65	4.9	23
169	Interpregnancy Interval and Adverse Pregnancy Outcomes: An Analysis of Successive Pregnancies. <i>Obstetrics and Gynecology</i> , 2017 , 130, 464-465	4.9	2
168	Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. <i>Biochemical Pharmacology</i> , 2017 , 144, 52-62	6	8
167	Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3396-3405	3.1	8
166	Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 881-889	5.5	6
165	Safety and effectiveness of Human Papillomavirus (HPV) vaccination: NCI of Milan position statement. <i>Vaccine</i> , 2017 , 35, 5227	4.1	1
164	Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy". <i>Journal of Minimally Invasive Gynecology</i> , 2017 , 24, 1243-1244	2.2	

163	Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study. <i>Gynecologic Oncology</i> , 2017 , 144, 90-95	4.9	55
162	Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery. <i>Journal of Minimally Invasive Gynecology</i> , 2017 , 24, 98-102	2.2	22
161	Laparoscopic Sentinel Node Mapping in Endometrial Cancer After Hysteroscopic Injection of Indocyanine Green. <i>Journal of Minimally Invasive Gynecology</i> , 2017 , 24, 89-93	2.2	24
160	Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017 , 208, 41-45	2.4	6
159	LION: Lymphadenectomy in ovarian neoplasms prospective randomized AGO study group led gynecologic cancer intergroup trial <i>Journal of Clinical Oncology</i> , 2017 , 35, 5500-5500	2.2	53
158	Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20 <i>Journal of Clinical Oncology</i> , 2017 , 35, 5501-55	5 0 1	91
157	A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in front-line treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC) <i>Journal of Clinical Oncology</i> , 2017 , 35, 5536-5536	2.2	2
156	Benign metastasizing leiomyoma (BML): A retrospective case series analysis of 8 patients (pts) Journal of Clinical Oncology, 2017 , 35, e22525-e22525	2.2	Ο
155	Involvement of AF1q/MLLT11 in the progression of ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 23246-23264	3.3	4
¹ 54	Sensitivity to chemotherapy of low-grade endometrial stromal sarcoma (LGESS) versus high-grade endometrial stromal sarcoma (HGESS) <i>Journal of Clinical Oncology</i> , 2017 , 35, 11072-11072	2.2	
153	Bulky mesonephric adenocarcinoma of the uterine cervix treated with neoadjuvant chemotherapy and radical surgery: report of the first case. <i>Tumori</i> , 2016 , 102,	1.7	2
152	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecologic Oncology</i> , 2016 , 143, 27-34	4.9	63
151	Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. <i>Annals of Oncology</i> , 2016 , 27, 1505-10	10.3	25
150	Is aortic lymphadenectomy indicated in locally advanced cervical cancer after neoadjuvant chemotherapy followed by radical surgery? A retrospective study on 261 women. <i>European Journal of Surgical Oncology</i> , 2016 , 42, 1512-8	3.6	
149	Egg Freezing in Childhood and Young Adult Cancer Survivors. <i>Pediatrics</i> , 2016 , 138,	7.4	7
148	FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results. <i>Tumori</i> , 2016 , 102, 103-7	1.7	20
147	Morcellation of undiagnosed uterine sarcoma: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 302-8	7	21
146	Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. <i>Gynecologic Oncology</i> , 2016 , 140, 425-9	4.9	6

145	Morcellator® Port-site Metastasis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential After Minimally Invasive Myomectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2016 , 23, 647	7 .2 2	12
144	Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma: A Systematic Review and Meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 371-80	3.5	10
143	Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence. <i>Journal of Minimally Invasive Gynecology</i> , 2016 , 23, 489-96	2.2	6
142	Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. <i>Annals of Oncology</i> , 2016 , 27, 487-93	10.3	40
141	Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 335-48	7	17
140	The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO,	2.2	8
139	Embryos need a cozy house. Journal of Gynecologic Oncology, 2016 , 27, e34	4	1
138	Morcellation of apparent benign uterine myoma: assessing risk to benefit ratio. <i>Journal of Gynecologic Oncology</i> , 2016 , 27, e37	4	5
137	Sentinel lymph node detection in endometrial cancer: does injection site make a difference?. Journal of Gynecologic Oncology, 2016 , 27, e23	4	7
136	Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 434.	5 ⁻² 4353	49
135	Female fertility preserving practices at a pediatric unit: a challenge of multiprofessional and multidisciplinary cooperation. <i>Tumori</i> , 2016 , 102, 174-7	1.7	5
134	Incorporating 3D laparoscopy for the management of locally advanced cervical cancer: a comparison with open surgery. <i>Tumori</i> , 2016 , 102, 393-7	1.7	9
133	Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. <i>Lancet Oncology, The</i> , 2016 , 17, 1137-1146	21.7	82
132	Surgical Management and Prognostic Factors of Vulvovaginal Melanoma. <i>Journal of Lower Genital Tract Disease</i> , 2016 , 20, e24-9	3.6	22
131	Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. <i>Gynecologic Oncology</i> , 2016 , 141, 461-465	4.9	39
130	Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). <i>Annals of Oncology</i> , 2016 , 27, 1006-1013	10.3	5
129	Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2016 , 143, 443-447	4.9	33
128	Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report. <i>Minerva Ginecologica</i> , 2016 , 68, 536-43	1.2	3

(2015-2015)

127	Incidence of port-site hernia following robotic-assisted sacrocolpopexy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015 , 194, 249-50	2.4	1
126	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 561-8	21.7	109
125	Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4204-10	3.1	31
124	Fertility-sparing surgery in early-stage cervical cancer patients: oncologic and reproductive outcomes. <i>International Journal of Gynecological Cancer</i> , 2015 , 25, 493-7	3.5	22
123	When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22 Suppl 3, S944-51	3.1	10
122	Pneumoperitoneum pressures during pelvic laparoscopic surgery: a systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015 , 195, 1-6	2.4	7
121	Treatment of Recurrent Endometrial Carcinoma: Progress Toward a More Personalized Approach. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3516	2.2	5
120	Peritoneal cytology as prognostic factor in cervical cancer. <i>Diagnostic Cytopathology</i> , 2015 , 43, 705-9	1.4	6
119	A critical assessment on the role of sentinel node mapping in endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2015 , 26, 252-4	4	11
118	Fertility-sparing surgery in high-risk ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2015 , 26, 350-1	4	8
117	Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures. <i>Gynecologic Oncology</i> , 2015 , 138, 78-82	4.9	51
116	How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced cervical cancer after neoadjuvant chemotherapy and type C radical hysterectomy?. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 1089-96	3.6	11
115	Sentinel node mapping using hysteroscopic injection of indocyanine green and laparoscopic near-infrared fluorescence imaging in endometrial cancer staging. <i>Journal of Minimally Invasive Gynecology</i> , 2015 , 22, 132-3	2.2	28
114	Implementation of laparoscopic approach for type B radical hysterectomy: a comparison with open surgical operations. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 34-9	3.6	62
113	Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial <i>Journal of Clinical Oncology</i> , 2015 , 33, 5502-5502	2.2	30
112	Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study <i>Journal of Clinical Oncology</i> , 2015 , 33, 5503-5503	2.2	8
111	Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. <i>Oncotarget</i> , 2015 , 6, 30859-75	3.3	25
110	Treatment of Early Ovarian Cancer 2015 , 419-427		

109	OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer <i>Journal of Clinical Oncology</i> , 2015 , 33, e16576-e16576	2.2	
108	Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): Results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial <i>Journal of Clinical Oncology</i> , 2015 , 33, 5569-5569	2.2	
107	A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. <i>Gynecologic Oncology</i> , 2014 , 133, 117-23	4.9	129
106	Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2014 , 134, 166-71	4.9	48
105	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 396-405	21.7	271
104	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 799-808	21.7	238
103	Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2014 , 210, 363.e1-363.e10	6.4	43
102	Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer?. <i>Oncology</i> , 2014 , 87, 293-9	3.6	6
101	Oophorectomy and hysterectomy and cancer incidence in the Cancer Prevention Study-II Nutrition Cohort. <i>Obstetrics and Gynecology</i> , 2014 , 124, 840-841	4.9	1
100	Fertility sparing surgery in early stage epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2014 , 25, 320-7	4	41
99	Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. <i>Journal of Gynecologic Oncology</i> , 2014 , 25, 22-9	4	21
98	High-risk borderline ovarian tumors: analysis of clinicopathological features and prognostic impact of different follow-up strategies. <i>Oncology</i> , 2014 , 87, 183-92	3.6	3
97	Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation. <i>Human Reproduction Update</i> , 2014 , 20, 944-51	15.8	14
96	Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 1256-61	3.5	10
95	Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 729-	34 ^{.5}	17
94	Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 891-8	3.6	24
93	Class II versus Class III radical hysterectomy in early cervical cancer: an observational study in a tertiary center. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 883-90	3.6	10
92	MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC) <i>Journal of Clinical Oncology</i> 2014 32, 5503-5503	2.2	7

91	A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers <i>Journal of Clinical Oncology</i> , 2014 , 32, 5519-5519	2.2	11
90	Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial <i>Journal of Clinical Oncology</i> , 2014 , 32, 5530-5530) ^{2.2}	2
89	Randomized phase II trial of NGR-hTNF with an anthracycline in platinum-refractory or -resistant ovarian cancer (OC) <i>Journal of Clinical Oncology</i> , 2014 , 32, 5523-5523	2.2	
88	Multicenter retrospective analysis of 31 patients with aggressive angiomyxoma <i>Journal of Clinical Oncology</i> , 2014 , 32, 10585-10585	2.2	
87	Laparoscopic versus open radical hysterectomy for stage IB2-IIB cervical cancer in the setting of neoadjuvant chemotherapy: a multi-institutional cohort study. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2007-15	3.1	34
86	Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study. <i>European Journal of Cancer</i> , 2013 , 49, 1065-72	7.5	16
85	Association between tumor diameter and lymphovascular space invasion among women with early-stage endometrial cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2013 , 123, 142-5	4	26
84	The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience. <i>Oncology</i> , 2013 , 85, 122-7	3.6	9
83	The role of lymphadenectomy in cervical cancer patients: the significance of the number and the status of lymph nodes removed in 526 cases treated in a single institution. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3948-54	3.1	45
82	Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Pagetß disease. <i>Gynecologic Oncology</i> , 2013 , 130, 90-4	4.9	29
81	Advanced ovarian cancer: omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor. <i>Gynecologic Oncology</i> , 2013 , 129, 92-6	4.9	20
80	High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy. <i>Case Reports in Oncology</i> , 2013 , 6, 21-4	1	1
79	Bevacizumab treatment and quality of life in advanced ovarian cancer. Future Oncology, 2013, 9, 951-4	3.6	2
78	Embryonal rhabdomyosarcoma of the uterine cervix in adults: a case report and literature review. <i>Journal of Lower Genital Tract Disease</i> , 2013 , 17, e12-7	3.6	10
77	Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study. <i>Gynecologic Oncology</i> , 2012 , 125, 673-6	4.9	51
76	Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. <i>Gynecologic Oncology</i> , 2012 , 126, 419-23	4.9	58
75	Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study. <i>Annals of Surgical Oncology</i> , 2012 , 19, 3849-55	3.1	45
74	Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. <i>BJOG: an International Journal of Obstetrics and Gyngerology</i> 2012 119, 800-9	3.7	55

73	The role of secondary surgery in recurrent ovarian cancer. <i>International Journal of Surgical Oncology</i> , 2012 , 2012, 613980	0.9	13
72	In vivo detection of choline in ovarian tumors using 3D magnetic resonance spectroscopy. <i>Investigative Radiology</i> , 2011 , 46, 377-82	10.1	32
71	Third-line chemotherapy with tyrosine kinase inhibitor (imatinib mesylate) in recurrent ovarian granulosa cell tumor: case report. <i>Journal of Obstetrics and Gynaecology Research</i> , 2011 , 37, 1864-7	1.9	9
70	New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. <i>Gynecologic Oncology</i> , 2011 , 122, 264-8	4.9	91
69	Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. <i>Gynecologic Oncology</i> , 2011 , 123, 553-6	4.9	55
68	Class III nerve-sparing radical hysterectomy versus standard class III radical hysterectomy: an observational study. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3469-78	3.1	41
67	Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. <i>Oncotarget</i> , 2011 , 2, 1265-78	3.3	52
66	Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. <i>European Journal of Cancer</i> , 2010 , 46, 2905-12	7.5	35
65	Class III NSRH: oncological outcome in 170 cervical cancer patients. <i>Gynecologic Oncology</i> , 2010 , 119, 192-7	4.9	16
64	A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 1569-75	3.5	15
63	Neoadjuvant chemoradiation followed by radical hysterectomy in FIGO Stage IIIB cervical cancer: feasibility, complications, and clinical outcome. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 1119-24	3.5	27
62	Nerve-sparing radical vaginectomy: two case reports and description of the surgical technique. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 794-7	3.5	3
61	Quality of life and sexual, bladder, and intestinal dysfunctions after class III nerve-sparing and class II radical hysterectomies: a questionnaire-based study. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 953-7	3.5	43
60	Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1707-16	9.7	1043
59	Hysteroscopy in endometrial cancer: new methods to evaluate transtubal leakage of saline distension medium. <i>American Journal of Obstetrics and Gynecology</i> , 2008 , 198, 214.e1-4	6.4	16
58	Sentinel Lymph Node Biopsy in Gynecologic Malignancies 2008 , 130-141		
57	Trends of determinants of hormone therapy use in Italian women attending menopause clinics, 1997-2003. <i>Menopause</i> , 2008 , 15, 164-70	2.5	16
56	Nerve-sparing radical hysterectomy in cervical cancer: evolution of concepts. <i>Gynecologic Oncology</i> , 2007 , 107, S119-21	4.9	26

55	Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis. <i>Gynecologic Oncology</i> , 2007 , 107, S150-4	4.9	46
54	Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 762-72	6.1	17
53	Incidental diagnosis of primary vaginal adenocarcinoma of intestinal type: a case report and review of the literature. <i>International Journal of Gynecological Pathology</i> , 2007 , 26, 490-3	3.2	16
52	Regional Therapy in Ovarian Cancer 2007 , 329-341		
51	Type II versus Type III nerve-sparing radical hysterectomy: comparison of lower urinary tract dysfunctions. <i>Gynecologic Oncology</i> , 2006 , 102, 256-62	4.9	71
50	Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2006 , 102, 333-7	4.9	78
49	Photodynamic therapy using a methyl ester of 5-aminolevulinic acid in recurrent Paget® disease of the vulva: a pilot study. <i>Gynecologic Oncology</i> , 2006 , 103, 581-6	4.9	66
48	Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. <i>European Journal of Surgical Oncology</i> , 2006 , 32, 671-5	3.6	82
47	A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2006 , 16 Suppl 1, 79-85	3.5	13
46	Factors associated with climacteric symptoms in women around menopause attending menopause clinics in Italy. <i>Maturitas</i> , 2005 , 52, 181-9	5	49
45	Lymphatic mapping for endometrial cancer: is hysteroscopic injection a safe technique for sentinel lymph node biopsy?. <i>American Journal of Obstetrics and Gynecology</i> , 2005 , 193, 1880-1; author reply 188	sf- 2	5
44	Prognostic factors in microinvasive cervical squamous cell cancer: long-term results. <i>International Journal of Gynecological Cancer</i> , 2005 , 15, 88-93	3.5	18
43	Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 560-6	9.7	352
42	CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 5202-14	12.9	45
41	Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 686-90	2.2	29
40	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. <i>Oncogene</i> , 2004 , 23, 8171-83	9.2	69
39	Nerve-sparing radical hysterectomy: a surgical technique for preserving the autonomic hypogastric nerve. <i>Gynecologic Oncology</i> , 2004 , 93, 307-14	4.9	105
38	Hysteroscopic injection of tracers in sentinel node detection of endometrial cancer: a feasibility study. <i>American Journal of Obstetrics and Gynecology</i> , 2004 , 191, 435-9	6.4	66

37	Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. <i>Oncology</i> , 2004 , 67, 376-81	3.6	26
36	Microinvasive squamous cell cervical carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 48, 251	- 6 1	17
35	False-negative sentinel node in patients with vulvar cancer: a case study. <i>International Journal of Gynecological Cancer</i> , 2003 , 13, 361-3	3.5	21
34	Management of peritoneal surface component of ovarian cancer. Surgical Oncology Clinics of North America, 2003 , 12, 561-83	2.7	26
33	Gonadoblastoma in androgen insensitivity syndrome: a case report. <i>Tumori</i> , 2003 , 89, 196-8	1.7	1
32	Nerve-sparing radical hysterectomy: a pilot study. <i>Tumori</i> , 2003 , 89, 497-501	1.7	6
31	Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 179-88	2.2	142
30	Risk of low bone density in women attending menopause clinics in Italy. <i>Maturitas</i> , 2002 , 42, 105-11	5	15
29	Neoadjuvant Chemotherapy and Radical Surgery Versus Exclusive Radiotherapy in Locally Advanced Squamous Cell Cervical Cancer: Results From the Italian Multicenter Randomized Study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 179-188	2.2	249
28	Role of secondary surgery in relapsed ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 37, 121-5	7	6
27	Gonadal malignant germ cell tumors express immunoreactive inhibin/activin subunits. <i>European Journal of Endocrinology</i> , 2001 , 145, 779-84	6.5	27
26	Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study. <i>Tumori</i> , 2001 , 87, 120-126	1.7	63
25	General and medical factors associated with hormone replacement therapy among women attending menopause clinics in Italy. <i>Menopause</i> , 2001 , 8, 290-5	2.5	21
24	Prognostic indicators in melanoma of the vulva. <i>Annals of Surgical Oncology</i> , 2000 , 7, 738-42	3.1	46
23	Determinants of hysterectomy and oophorectomy in women attending menopause clinics in Italy. <i>Maturitas</i> , 2000 , 36, 19-25	5	27
22	Risk factors for genital prolapse in non-hysterectomized women around menopause. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2000 , 93, 135-140	2.4	81
21	Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. <i>Gynecologic Oncology</i> , 1998 , 69, 151-6	4.9	29
20	Endometrioid Carcinoma of the Ovary: A Retrospective Analysis of 106 Cases. <i>Tumori</i> , 1998 , 84, 552-557	71.7	17

19	Adult Granulosa Cell Tumor of the Ovary: A Clinico Pathologic Study of 35 Cases. <i>Tumori</i> , 1998 , 84, 60-6	41.7	18
18	Radio-Chemotherapy of Vulvar Cancer. <i>Tumori</i> , 1998 , 84, 250-251	1.7	1
17	Early ovarian cancer: Is there a role for systematic pelvic and para-aortic lymphadenectomy?. <i>International Journal of Gynecological Cancer</i> , 1998 , 8, 103-108	3.5	27
16	Conservative surgery in high-risk epithelial ovarian carcinoma. <i>Journal of the American College of Surgeons</i> , 1997 , 185, 457-460	4.4	9
15	Conservative surgery in high-risk epithelial ovarian carcinoma. <i>Journal of the American College of Surgeons</i> , 1997 , 185, 457-60	4.4	52
14	Malignant degeneration in leiomyomatosis peritonealis disseminata. <i>Gynecologic Oncology</i> , 1996 , 61, 272-4	4.9	47
13	Fallopian tube cancer: incidence and role of lymphatic spread. <i>Gynecologic Oncology</i> , 1996 , 62, 199-202	4.9	54
12	Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. <i>Gynecologic Oncology</i> , 1996 , 62, 360-5	4.9	99
11	Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. <i>Cancer</i> , 1996 , 77, 1472-8	6.4	70
10	Radical surgery after induction chemotherapy in locally advanced cervical cancer. A feasibility study. <i>International Journal of Gynecological Cancer</i> , 1995 , 5, 296-300	3.5	15
9	Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. <i>Journal of the National Cancer Institute</i> , 1995 , 87, 1463-9	9.7	152
8	Surgical staging for epithelial ovarian tumors of low malignant potential. <i>International Journal of Gynecological Cancer</i> , 1994 , 4, 310-314	3.5	16
7	Intestinal operations during surgical procedures for epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1994 , 4, 320-323	3.5	7
6	The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study. <i>British Journal of Cancer</i> , 1994 , 69, 961-6	8.7	6
5	Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. <i>European Journal of Cancer</i> , 1994 , 30A, 363-9	7.5	97
4	Potentials of cell kinetics in the management of patients with ovarian cancers. <i>European Journal of Cancer</i> , 1992 , 28, 386-90	7.5	9
3	The role of appendectomy in surgical procedures for ovarian cancer. <i>Gynecologic Oncology</i> , 1992 , 46, 42-4	4.9	31
2	Pelvic and para-aortic lymphadenectomy in cancer of the ovary. <i>Baillierem Clinical Obstetrics and Gynaecology</i> , 1989 , 3, 131-42		46

Usefulness and Potential Pitfalls of Sialic Acid Determination in Sera of Patients with Ovarian Tumors. *International Journal of Biological Markers*, **1986**, 1, 39-46

2.8 5